{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06179160",
            "orgStudyIdInfo": {
                "id": "INCB161734-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-507091-47-00",
                    "type": "REGISTRY",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Incyte Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
            "officialTitle": "A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-in-participants-with-advanced-or-metastatic-solid-tumors-with-kras-mutation"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-12",
            "studyFirstSubmitQcDate": "2023-12-20",
            "studyFirstPostDateStruct": {
                "date": "2023-12-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Incyte Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors"
            ],
            "keywords": [
                "INCB161734",
                "KRASG12D Mutation",
                "pancreatic ductal adenocarcinoma (PDAC)",
                "colorectal cancer (CRC)",
                "non-small cell lung cancer (NSCLC)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 322,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1a: Dose Escalation monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "INCB161734 at the protocol-defined dose strength based on cohort assignment.",
                    "interventionNames": [
                        "Drug: INCB161734"
                    ]
                },
                {
                    "label": "Part 1b: Dose Expansion monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "INCB161734 at the protocol-defined dose strength based on cohort assignment.",
                    "interventionNames": [
                        "Drug: INCB161734"
                    ]
                },
                {
                    "label": "Part 1c: Pharmacodynamic cohort",
                    "type": "EXPERIMENTAL",
                    "description": "INCB161734 at the protocol-defined dose strength based on cohort assignment.",
                    "interventionNames": [
                        "Drug: INCB161734"
                    ]
                },
                {
                    "label": "Part 2a: Dose Escalation combination",
                    "type": "EXPERIMENTAL",
                    "description": "INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.",
                    "interventionNames": [
                        "Drug: INCB161734",
                        "Drug: Cetuximab",
                        "Drug: Retifanlimab"
                    ]
                },
                {
                    "label": "Part 2b: Dose Expansion combination",
                    "type": "EXPERIMENTAL",
                    "description": "INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.",
                    "interventionNames": [
                        "Drug: INCB161734",
                        "Drug: Cetuximab",
                        "Drug: Retifanlimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INCB161734",
                    "description": "INCB161734 will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 1a: Dose Escalation monotherapy",
                        "Part 1b: Dose Expansion monotherapy",
                        "Part 1c: Pharmacodynamic cohort",
                        "Part 2a: Dose Escalation combination",
                        "Part 2b: Dose Expansion combination"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetuximab",
                    "description": "Cetuximab will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 2a: Dose Escalation combination",
                        "Part 2b: Dose Expansion combination"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Retifanlimab",
                    "description": "Retifanlimab will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 2a: Dose Escalation combination",
                        "Part 2b: Dose Expansion combination"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Dose Limiting Toxicities (DLTs)",
                    "description": "Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with Treatment-emergent Adverse Events (TEAEs)",
                    "description": "Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab and retifanlimab.",
                    "timeFrame": "Up to 2 years and 90 days"
                },
                {
                    "measure": "Number of participants with TEAEs leading to dose modification or discontinuation",
                    "description": "Number of participants with TEAEs leading to dose modification or discontinuation.",
                    "timeFrame": "Up to 2 years and 90 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "INCB161734 pharmacokinetic (PK) in Plasma",
                    "description": "INCB161734 concentration in plasma.",
                    "timeFrame": "Up to approximately 90 days"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Defined as having a best overall Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Disease Control Response (DCR)",
                    "description": "Defined as having a best overall response of CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or death due to any cause if occurring sooner than progression.",
                    "timeFrame": "Up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u226518 years old\n* Locally-advanced or metastatic solid tumor with KRAS G12D mutation\n* Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment to improve the disease outcome\n* Cohort specific requirements as follows:\n\n  * Part 1A: Histologically or cytologically confirmed malignant solid tumor of any tissue origin\n  * Part 1B\n\n    * Disease group 1: diagnosis of PDAC\n    * Disease group 2: diagnosis of CRC\n    * Disease group 3: diagnosis of NSCLC\n    * Disease group 4: diagnosis of other advanced solid tumor and not part of Disease groups 1, 2 and 3\n  * Parts 2A and 2B\n\n    * Combination 1: Diagnosis of CRC or CRC\n    * Combination 2: Diagnoses of PDAC, CRC or NSCLC\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Prior treatment with any KRAS G12D inhibitor\n* Known additional invasive malignancy within 1 year of the first dose of study drug\n* History of organ transplant, including allogeneic stem cell transplantation\n* Significant, uncontrolled medical condition\n* History or presence of an ECG abnormality\n* Inadequate organ function\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Incyte Corporation Call Center (US)",
                    "role": "CONTACT",
                    "phone": "1.855.463.3463",
                    "email": "medinfo@incyte.com"
                },
                {
                    "name": "Incyte Corporation Call Center (ex-US)",
                    "role": "CONTACT",
                    "phone": "+800 00027423",
                    "email": "eumedinfo@incyte.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Incyte Medical Monitor",
                    "affiliation": "Incyte Corporation",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85054",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "UCLA Healthcare Hematology-Oncology",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90404",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institue At Healthone",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Hackensack University Medical Center",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Weill Cornell Medicine",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10022",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Md Anderson Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Chris Obrien Lifehouse",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Camperdown",
                    "state": "New South Wales",
                    "zip": "02050",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.88965,
                        "lon": 151.17642
                    }
                },
                {
                    "facility": "St Vincent'S Hospital Sydney",
                    "status": "RECRUITING",
                    "city": "Darlinghurst",
                    "state": "New South Wales",
                    "zip": "02010",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.87939,
                        "lon": 151.21925
                    }
                },
                {
                    "facility": "The Alfred Hospital",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "03004",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Peter Maccallum Cancer Centre",
                    "status": "RECRUITING",
                    "city": "North Melbourne",
                    "state": "Victoria",
                    "zip": "3051",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.80132,
                        "lon": 144.95822
                    }
                },
                {
                    "facility": "Linear Clinical Research",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "06009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "Cliniques Universitaires Ucl Saint-Luc",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Brussels",
                    "zip": "01200",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 50.85045,
                        "lon": 4.34878
                    }
                },
                {
                    "facility": "The Ottawa Hospital Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Toulouse",
                    "zip": "31059",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Villejuif Cedex",
                    "zip": "94805",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Irccs Istituto Clinico Humanitas",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Rozzano",
                    "zip": "20089",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.38193,
                        "lon": 9.1559
                    }
                },
                {
                    "facility": "Hospital General Universitario Vall D Hebron",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}